|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.24 CHF | +0.59% |
|
+2.09% | +8.80% |
| 04:06am | Can Bayer Still Recover? |  |
| 01:19am | Novartis: Pluvicto psmaddition data to highlight efficacy in metastatic hormone-sensitive prostate cancer | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 155.23 | +3.08% | 21 | ||||||
| 1,210 | +18.76% | 29 | ||||||
| 252.96 | +10.31% | 24 | ||||||
| 252.9 | +19.12% | 29 | ||||||
| 360.76 | +9.96% | 17 | ||||||
| 221.62 | +18.15% | 21 | ||||||
| 129.74 | +14.81% | 27 | ||||||
| 307.99 | +6.79% | 23 | ||||||
| 352.23 | +6.23% | 30 | ||||||
| 157.83 | +20.76% | 29 | ||||||
| 29.19 | +13.17% | 27 | ||||||
| 62.96 | +7.55% | 25 | ||||||
| 548.1 | +27.34% | 29 | ||||||
| 97.1 | +26.64% | 23 | ||||||
| 20.32 | +7.03% | 20 | ||||||
| 10,096.67 | +27.82% | 15 | ||||||
| 6,123.53 | +16.53% | 15 | ||||||
| 82.08 | +61.1% | 17 | ||||||
| 48.68 | +24.1% | 19 | ||||||
| 4.175 | +22.35% | 17 | ||||||
| Average | 1,025.7 | +18.08% | 23 | ||||||
| Weighted average by Cap. | 675.7 | +15.14% | 25 |
- Stock Market
- Equities
- NOVN Stock
- Sector Novartis AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition